Meta Platforms Inc. dragged the tech sector into the red on Thursday, triggering a selloff that pushed the S&P 500 and Nasdaq Composite below their 50-day moving averages. The decline wasn’t just a blip; it signaled a genuine fracture in the artificial intelligence narrative that has propped up valuations for the past eighteen months. While growth stocks bled, the “Buffett market“—defined by low-valuation, high-dividend value stocks—continued to climb, creating a bizarre divergence that has left market strategists scrambling to explain the disconnect.
The shift is stark. For years, the S&P 500 has been a proxy for big tech. Now, the index is balancing on a knife-edge between two distinct economies. One is the speculative, capital-intensive AI buildout. The other is the steady, cash-generating industrial base. Investors are no longer asking if the market will go up; they are asking which part of the market will lead. The answer, as of this week’s trading session, is complicated. Meta’s earnings report, released after the bell on Wednesday, served as the catalyst for the Thursday morning rout. The company guided for a massive increase in capital expenditures, spooking shareholders who feared the return of the “spend at all costs” era seen in the early 2010s.
The AI Premium Cracks
Meta, Inc. shares fell nearly 5% in pre-market trading before stabilizing, but the damage to sentiment was immediate. The stock’s decline dragged down peers like Microsoft Corp. and NVIDIA Corp., which have been the engines of the recent bull run. But the contagion went deeper. Moderna Inc., a name that had quietly recovered its footing in 2025, crashed more than 12% on thin volume. Why did a biotech firm get caught in a tech rout? Because the market is treating all high-multiple growth stocks as a single, fragile asset class. If the AI thesis wobbles, the liquidity that propped up smaller biotech names evaporates overnight.
Trading volume on the Nasdaq was 14% above the 30-day average, a clear sign of institutional redistribution rather than panic selling by retail investors. “We are seeing a rotation, not a retreat,” said James Henderson, a senior portfolio manager at a mid-sized Chicago hedge fund. “Clients are simply moving from stories to earnings. The AI capital expenditure guidance was a red flag for anyone watching free cash flow closely.” The market didn’t crash because the economy is breaking. It crashed because the pricing model for future growth has shifted from “infinite potential” to “proven ROI.”
Moderna’s Unlikely Fall
Moderna’s plunge is the outlier that defines this specific session. The company reported solid R&D progress on its universal flu vaccine, yet the stock sold off. This decoupling of fundamentals from price action is rare. It suggests that investors are de-risking from any stock that relies heavily on future approvals rather than current cash generation. The 50-day moving average is a technical support level that has held firm for six months. Breaking below it usually signals the start of a multi-week correction. For Moderna, the break was violent. It closed 142 points lower, wiping out its entire 2026 year-to-date gain in a single afternoon.
Analysts at Goldman Sachs noted that the biotech sector has become a “beta play” on the Nasdaq. When tech wobbles, biotech falls harder. This correlation has tightened dangerously. It’s a reminder that liquidity is the lifeblood of these markets. When the AI trade cools, the marginal buyer for high-beta stocks disappears. The result is a vacuum. Moderna is the canary in the coal mine for the broader growth sector. If the vaccine maker cannot find a floor, other small-cap growth stocks will follow.
The Buffett Portfolio Holds Firm
While Nasdaq tech bled, the Dow Jones Industrial Average found support. More importantly, the Russell 1000 Value Index, a proxy for the “Buffett market,” gained 0.8%. This is the crucial data point. Warren Buffett’s Berkshire Hathaway has historically favored companies with wide moats, low debt, and consistent dividends. These are the stocks that are thriving right now. Energy majors, bank stocks, and industrial conglomerates are seeing inflows as investors seek safety without abandoning equity exposure entirely. The split is not just between growth and value; it is between speculation and certainty.
Berkeley’s own data shows that the premium paid for growth stocks over value stocks has narrowed to its tightest level since 2019. This is not a minor technicality. It represents a fundamental re-rating of risk. Investors are no longer willing to pay a 40x earnings multiple for a company with negative cash flow. They are happy to pay 15x for a company with 5% dividend yield and a fortress balance sheet. The “Buffett market” is thriving because it offers tangible assets in a world of intangible hype. It’s the only place where the numbers add up.
What Comes Next for the S&P 500
The next 72 hours will be critical. The Federal Reserve’s FOMC meeting minutes are due this Friday. Markets are pricing in a 60% chance of a rate hold, but the tone of the statement will matter more than the decision itself. If the Fed hints at higher-for-longer rates due to sticky inflation, the AI trade will face further pressure. High rates make the distant future profits of tech companies less valuable in present terms. Conversely, if the Fed signals flexibility, a relief rally in Nasdaq stocks is likely.
Investors should watch the 50-day moving average of the S&P 500. It currently sits at 5,420. If the index closes below this level on Friday, it confirms a trend change. The “Buffett market” will likely continue to outperform, but the volatility in tech will remain elevated. This is not a market for chasing highs. It is a market for patience. The days of easy money in tech are over. The era of selective, fundamental investing has returned.
Frequently Asked Questions
Why did Moderna crash when its earnings were stable?
Moderna’s crash was driven by sector-wide de-risking rather than company-specific news. As a high-beta growth stock, it is highly correlated with Nasdaq tech sentiment. When Meta’s AI spending concerns triggered a sell-off in tech, liquidity drained from similar high-multiple growth names, causing Moderna to fall despite solid R&D updates. It is a victim of the broader retreat from speculative growth assets.
Is the “Buffett market” a safe haven right now?
Not a haven, but a relative shield. Value stocks are outperforming growth because they offer tangible cash flows and dividends, which provide a floor for valuations. However, they are not immune to macro shocks. If the economy deteriorates sharply, even value stocks will fall. But in the current environment of high rates and tech uncertainty, the “Buffett market” offers the best risk-reward profile for income-focused investors.
Source: Yahoo Finance
This article was compiled by the IndiaBBCNews editorial system from verified international news sources. Facts have been independently reviewed. Original reporting: Yahoo Finance.
